Miniprobe endoscopic ultrasonography (mEUS) combines high-resolution imaging of the gastrointestinal (GI) wall and bile ducts with ease of applicability during routine endoscopy. This narrative review aims to provide an overview of known and emerging fields of application for mEUS in gastrointestinal endoscopy. After its initial development in pancreatobiliary scenarios in the early 1990s, mEUS has been recently reconsidered a third-space endoscopic technique that is progressively developing and spreading for the treatment of early gastrointestinal neoplastic lesions. The high spatial resolution of mEUS provides an accurate assessment of the degree of submucosal invasion in early esophageal, gastric, and colorectal neoplasia, while the small caliber of catheters allows for mEUS employment in settings where standard echoendoscopes are impractical (e.g., severe stenoses or proximal colonic lesions). Beyond cancer staging, mEUS offers point-of-care characterization of subepithelial lesions by defining the layer of origin and echo-pattern, eventually defining endoscopic resectability, but definitive diagnosis remains histological. In pancreatobiliary diseases, miniprobe intraductal ultrasonography (IDUS) shows its strongest application for indeterminate biliary strictures when endoscopic retrograde cholangiopancreatography (ERCP)-based sampling strategies and brushing cytology show inconclusive diagnoses, and in choledocholithiasis, particularly for the detection of small stones/sludge and confirmation of duct clearance. IDUS is also valuable for the staging of ampullary tumors, for longitudinal extension mapping in hilar cholangiocarcinoma and for selected portal biliopathy scenarios. Overall, mEUS and IDUS are high-resolution adjuncts that can meaningfully refine local decision-making in the treatment of superficial epithelial/subepithelial tumors or lesions involving the bile ducts. Limitations include shallow penetration, lack of tissue acquisition capability, a relative increase in post-ERCP pancreatitis risk for intraductal use, and substantial cost with limited availability in lower-volume centers.

Background: Liver histology remains the gold standard for assessing liver steatosis (LS); however, non-invasive methods are increasingly being explored in clinical practice. This study aimed to evaluate the agreement between magnetic resonance imaging (MRI) and liver histology in quantifying LS in patients with morbid obesity undergoing bariatric surgery (BS). Methods: This ancillary study is part of a prospective, double-blind, multicenter, randomized placebo-controlled trial investigating the effects of preoperative omega-3 polyunsaturated fatty acid supplementation on liver volume in morbidly obese patients undergoing BS. The parent trial yielded negative results, and randomization arm was retained as a covariate in all analyses. Patients underwent MRI within 2 days before surgery, followed by intraoperative wedge resection and TruCore needle liver biopsy. Agreement between MRI and histology was assessed using the intraclass correlation coefficient (ICC) and Cohen’s kappa coefficient (K) for both macro- and microvesicular steatosis. Results: Thirty-seven patients were enrolled; paired MRI and biopsy data were available for thirty-one (83.8%). Moderate and statistically significant agreement was observed between MRI and both TruCore (ICC: 0.52, p = 0.002; K: 0.42, p = 0.007) and wedge-resection (ICC: 0.53, p = 0.001; K: 0.29, p = 0.044) biopsies for macrovesicular steatosis. The MRI-derived values were systematically lower than histological estimates for macrovesicular steatosis (mean MRI: 23.4% vs. histology: 36.7–37.1%). No significant agreement was identified for microvesicular steatosis with either biopsy technique. Conclusions: In morbidly obese patients, MRI demonstrates only moderate agreement with liver histology for macrovesicular steatosis and is unreliable for microvesicular steatosis. The systematic underestimation of macrovesicular steatosis by MRI warrants caution when this modality is used as a standalone decision-making tool in this population. Further studies in larger and more heterogeneous cohorts are needed to better define the performance boundaries of MRI-derived fat-fraction measurement across the spectrum of obesity and metabolic liver disease.

Objectives: This study aimed to examine the association between the dangling choroid plexus sign and fetal structural, chromosomal, and genetic abnormalities, as well as to define the normal range of lateral ventricular width and the ratio of choroid plexus width to lateral ventricular width at 14–17 weeks of gestation. Methods: This retrospective study analyzed ultrasound images from early fetal anatomy scans performed between January 2018 and July 2025 at two tertiary fetal medicine centres. In centre A, 6063 singleton pregnancies underwent routine scans at 11–13 and 14–17 weeks. In centre B, 776 fetuses with suspected abnormalities or increased nuchal translucency at 11–13 weeks were reassessed at 14–17 weeks. Additionally, 400 fetuses without obvious abnormalities at 14–17 weeks were used to determine normal ventricular measurements. Results: In normal fetuses, the mean lateral ventricular width was 6.90 mm (95% CI 6.81–6.99) and the mean choroid plexus-to-ventricle ratio was 0.85 (95% CI 0.84–0.86). A dangling choroid plexus was identified in 38 fetuses (0.16% in routine and 3.6% in high-risk populations). Out of 38 cases of dangling choroid plexus, 37 were associated with additional structural defects, chromosomal abnormalities, or single-gene disorders. Chromosomal abnormalities were found in 11/30 tested cases, most commonly trisomy 21. The most common defects observed on initial or subsequent scans were ventriculomegaly, cardiac defects, and abnormal posterior fossa. Conclusions: A dangling choroid plexus at 14–17 weeks is a sonographic marker associated with major fetal abnormalities and should prompt detailed anatomical assessment and consideration of genetic testing.

Morbid obesity is a chronic condition characterized by metabolic disorders and low-grade chronic inflammation, both of which are closely linked to insulin resistance and adipokine dysregulation. In addition to its systemic effects, obesity also leads to structural and functional changes in the skin, supporting its role as an active metabolic and immunological organ. This study analyzed skin lesions occurring in individuals with morbid obesity and explored their potential relevance in the context of metabolic risk and treatment response rather than establishing clinically validated tools. The focus was on how excess adipose tissue affects the skin through metabolic, hormonal and mechanical mechanisms. Although this review focuses on morbid obesity, many of the included studies examine general obesity without separating its severity. Therefore, the findings may not fully reflect patients with BMI ≥ 40 kg/m2 and should be interpreted with caution. Three main areas were considered: the pathophysiological mechanisms underlying obesity-related skin lesions, selected dermatological manifestations as potential markers associated with metabolic risk, and changes in these manifestations during pharmacological, surgical, and lifestyle interventions. Available studies show that acanthosis nigricans and multiple acrochordons are consistently associated with insulin resistance, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease. An increase in BMI is also associated with impairment of the epidermal barrier, changes in the composition of skin lipids, and modifications of the skin microbiome, while biomechanical factors promote the development of chronic inflammation in the intertriginous areas. It has been shown that normalization of metabolic parameters achieved through GLP-1-based pharmacotherapy, bariatric surgery, or lifestyle changes can improve some skin manifestations, especially acanthosis nigricans. However, it should be emphasized that most available data are based on cross-sectional or observational studies, and validated composite dermatological indices are still unavailable. Skin changes in patients with morbid obesity often reflect underlying metabolic and hormonal disturbances. They may have potential as additional, non-invasive clinical clues, but they should not be treated as independent tools for risk assessment or treatment monitoring. At present, most evidence shows associations only, and it is unclear whether these findings add meaningful predictive value beyond standard metabolic markers. More prospective studies are needed to confirm their clinical usefulness and to define their role in assessing metabolic risk and monitoring treatment over time.

Acute myocardial infarction (AMI), a life-threatening event caused by cardiomyocyte death due to oxygen deprivation, drives cardiac dysfunction through ferroptosis—an iron-dependent cell death mechanism involving lipid peroxidation. By delivering multifunctional cargoes with low immunogenicity, extracellular vesicles (EVs) hold the therapeutic potential to inhibit cardiomyocyte ferroptosis through the regulation of iron metabolism and the mitigation of oxidative damage. Their dual role as targeted drug carriers and natural imaging probes enhances precision in AMI management. EVs enable the non-invasive tracking of biodistribution and therapeutic responses in real time when integrated with molecular imaging technology, offering insights into cardiac repair mechanisms. This synergy between EV-based therapy and advanced imaging presents a novel strategy for AMI diagnosis and targeted intervention.

Background: Dyspnea is a common reason for emergency medical service (EMS) interventions and is associated with a substantial risk of severe clinical course, complications, and hospital admission. Its differential diagnosis in the prehospital setting remains challenging due to the limited availability of imaging modalities. Point-of-care ultrasound (POCUS), including lung ultrasound (LUS), is a rapid, field-applicable technique recommended in numerous acute respiratory diagnostic scenarios. Objective: To evaluate the use of lung ultrasound in the prehospital setting and its association with the precision of diagnoses related to respiratory failure, the frequency of transport to the emergency department (ED) among patients presenting with dyspnea/respiratory failure, and to characterize the profile of sonographic findings with their correlation to clinical diagnostic categories. Additionally, transport rates in the study population were compared with aggregated regional data for the Masovian Voivodeship (excluding the analyzed county). Methods: A retrospective observational study was conducted on EMS interventions performed between 01 January 2025 and 30 June 2025 in Legionowo County (N = 353). The analysis included ICD-10 codes assigned in prehospital documentation (one primary code and up to two additional codes) in patients presenting with dyspnea and/or respiratory failure, the performance of ultrasound examination, and resulting LUS findings (absence of pleural sliding and/or lung point; B-lines; consolidations; C-lines; pleural effusion). Descriptive analyses, frequency comparison tests (χ2/Fisher), estimation of relative risk (RR) with 95% confidence intervals (CI), and agreement analysis using Cohen’s kappa coefficient (κ) between etiological categories derived from ICD-10 codes and those inferred from LUS profiles were performed (κ with 95% CI estimated using bootstrap resampling). The study was reported in accordance with the STROBE guidelines for observational studies. Additionally, the distribution of ICD-10 coding and the proportion of hospital transports across the entire Masovian Voivodeship were compared with those observed in the analyzed area. Results: Ultrasound examination was performed in 72/353 (20.4%) EMS interventions; transport to the emergency department occurred in 239/353 (67.7%) cases. The most frequent clinical categories based on ICD-10 codes were: general/symptom-based 182/353 (51.6%), inflammatory 77/353 (21.8%), obstructive 66/353 (18.7%), and cardiological 20/353 (5.7%). Among abnormal LUS findings, the most common were B-lines (43/72; 61.4%) and consolidations (29/72; 41.4%). Consolidations were strongly associated with the inflammatory category (OR 9.72; p < 0.001), whereas B-lines were associated with the cardiological category (OR 23.41; p = 0.0011) among cases in which LUS was performed. Ultrasound use was associated with a higher frequency of assigning at least one targeted (non-symptom-based) diagnosis within ICD coding: 53/72 (73.6%) vs. 111/278 (39.9%), RR 1.84 (95% CI 1.51–2.25; p < 0.001). Agreement between the ICD-10 etiological category (inflammatory/cardiological/obstructive/other) and the category inferred from the LUS profile was moderate: κ = 0.36 (95% CI 0.21–0.51), with an observed agreement of 54.2%. Compared with aggregated regional data (Masovian Voivodeship excluding the analyzed county), the overall transport rate for comparable ICD-10 codes was lower in the study unit: 279/409 (68.2%) vs. 11,351/13,785 (82.3%), RR 0.83 (95% CI 0.78–0.89; p < 0.001). The largest differences were observed for dyspnea (R06.0: 72.9% vs. 88.2%; RR 0.83) and obstructive codes (J44/J45/J46 combined: 43.1% vs. 67.0%; RR 0.64). Conclusions: In this retrospective analysis, an EMS unit with systematically implemented ultrasound demonstrated a lower frequency of hospital transport for selected dyspnea/respiratory failure codes compared with regional data and greater precision in ICD-10 diagnostic coding in cases where ultrasound was performed. The profile of LUS findings correlated with clinical categories in a manner consistent with existing literature.

Background: Progesterone receptor (PR) status plays an important role in guiding hormone therapy decisions in breast cancer. In current practice, PR expression is assessed manually from immunohistochemistry (IHC) slides, which can be time-consuming and may vary between pathologists. This study aims to develop an automated and interpretable framework for PR-IHC analysis to improve consistency and efficiency. Methods: In this work, we developed an AI-assisted pipeline that combines nuclei segmentation, classification, and scoring for PR-IHC images. A fine-tuned Cellpose model was used to segment individual nuclei. The segmented nuclei were then analyzed using a DAB intensity-based approach to classify them into four categories: negative, weak, moderate, and strong. These results were further combined to generate Allred scores. The system was evaluated on 250 PR-IHC images with annotations provided by expert pathologists. Results: The framework achieved strong segmentation performance (F1-score = 0.85, IoU = 0.74) and high classification accuracy (macro F1-score = 0.95). The method also performed well when applied to ER-IHC images without additional retraining. Conclusions: The proposed framework provides a reliable and interpretable approach for automated PR-IHC scoring. It helps reduce manual effort, improves consistency in evaluation, and shows potential for practical use in digital pathology settings.

Background/Objectives: Early detection of postnatal growth failure (PGF) is essential for optimizing nutritional management in preterm infants, as PGF is associated with adverse neurodevelopmental outcomes. Early prediction remains difficult because postnatal growth is influenced by multiple clinical factors including gestation age, birth weight, nutritional status, and comorbidities. Machine-learning approaches have been proposed to predict complex neonatal outcomes. This study compared the predictive performance of neonatologists with that of a machine-learning model for predicting PGF. Methods: PGF was defined as a decrease in weight z-score greater than 1.28 at discharge compared with birth. A machine-learning model based on extreme gradient boosting (XGBoost) was trained using a dataset of 7954 very low birth weight (VLBW) infants. Nine neonatologists independently assessed 100 clinical cases through a questionnaire-based evaluation, including 50 patients with PGF. Predictive performance was evaluated using seven metrics: area under the receiver operating characteristic curve (AUROC), accuracy, error rate, positive predictive value (PPV), sensitivity, specificity, and F1 score. Results: The neonatologists had a median of 5 years (range: 4–10 years) of clinical experience. The median prediction score among the neonatologists was 52/100 (range, 44–60), whereas the XGBoost model achieved 79/100. The XGBoost model achieved an AUROC of 0.79, accuracy of 0.79, error rate of 0.21, sensitivity of 0.82, and an F1 score of 0.80, demonstrating superior overall performance compared to the neonatologists. In addition, the XGBoost model had a lower error rate than the neonatologists (0.21 vs. 0.49), whereas specificity (0.76 vs. 0.86) and PPV (0.77 vs. 0.53) did not differ significantly. Conclusions: The machine-learning model demonstrated superior or comparable predictive performance to that of neonatologists in detecting PGF. Machine-learning-based prediction models may support early risk stratification and targeted nutritional management in VLBW infants.

Background and Clinical Significance: To describe two cases within the spectrum of non-myopic foveomacular retinoschisis, including stellate non-hereditary idiopathic foveomacular retinoschisis (SNIFR) and central anomalous retinoschisis with mid-peripheral traction (CARPET), and to highlight the role of multimodal imaging in identifying vitreoretinal traction in their pathogenesis and management. Case Presentation:First Case Report: A 57-year-old man presenting with bilateral visual decline. Multimodal imaging, including spectral-domain and en face optical coherence tomography (OCT), demonstrated characteristic features of SNIFR, with schisis at the Henle fibre layer and outer plexiform layer and persistent posterior hyaloid adhesion. Medical treatment was ineffective. Over two years, complete posterior vitreous detachment occurred, followed by spontaneous anatomical resolution of the schisis and full visual recovery. Second Case Report: A 63-year-old man with severe unilateral visual loss. Imaging revealed marked mid-peripheral vitreoretinal traction extending toward the posterior pole; associated with foveoschisis, central neurosensory detachment, and an outer lamellar macular hole, consistent with CARPET syndrome. The patient underwent pars plana vitrectomy with traction release. Postoperatively, complete anatomical resolution of both macular and peripheral schisis was achieved, with partial visual recovery. Conclusions: These cases support vitreoretinal traction as an important pathogenic mechanism in selected forms of non-myopic foveomacular retinoschisis. SNIFR may resolve spontaneously following posterior vitreous detachment, whereas CARPET represents a more severe tractional phenotype that may require surgical intervention. Careful multimodal imaging assessment of the vitreoretinal interface is essential for accurate diagnosis and management. These findings further characterise CARPET and expand the clinical spectrum of traction-related non-myopic foveomacular retinoschisis.

Ototoxicity represents a clinically significant complication of anticancer therapy in pediatric patients. Cytotoxic agents used in oncology, particularly platinum-based chemotherapy, may induce damage to the auditory and vestibular systems, resulting in hearing loss, tinnitus, and balance disturbances. Even mild hearing impairment during childhood may negatively affect speech perception, language development, communication abilities, and subsequent educational and psychosocial functioning. This narrative review aims to synthesize current evidence on treatment-related ototoxicity in children, with particular focus on commonly implicated therapies, clinical consequences, diagnostic approaches, and potential preventive strategies. A focused literature search was conducted in PubMed for publications from 2019 to 2025 addressing ototoxicity associated with pediatric anticancer treatment and audiological monitoring methods. The analysis indicates that platinum-based compounds, especially cisplatin and carboplatin, remain the primary agents associated with ototoxicity, with reported incidence ranging from approximately 20–70% for cisplatin and 10–30% for carboplatin. Additional risk factors include young age, baseline hearing status, renal function, and exposure to other ototoxic agents such as aminoglycoside antibiotics. Early detection relies on comprehensive audiological monitoring combining behavioral and objective methods, including pure-tone audiometry, extended high-frequency audiometry, otoacoustic emissions, and auditory brainstem response testing. Standardized grading systems such as ASHA, Brock, Chang, and SIOP Boston criteria play a key role in identifying and classifying ototoxic changes. Emerging research focuses on improved monitoring protocols, biomarker identification, and the development of otoprotective strategies, including sodium thiosulfate and experimental molecular therapies. Implementing systematic hearing monitoring and preventive strategies is essential to reduce long-term auditory complications and improve quality of life in pediatric cancer survivors.